Despite guidelines calling for genetic mutation testing in certain patients with lung cancer, three new surveys fielded by Harris Interactive reveal a disconnect in understanding of and communication about genetic mutation testing among healthcare professionals and cancer patients. Results of the surveys were announced by Boehringer Ingelheim Pharmaceuticals, Inc., who sponsored the surveys in partnership with the Association of Community Cancer Centers (ACCC), ONS:Edge and the National Lung Cancer Partnership (NLCP).
Click to view the survey results here!
